CONTACT: Mike Ferlazzo: 570-214-7410, 515-450-2908 (c), firstname.lastname@example.org
FOR IMMEDIATE RELEASE
Feb. 13, 2013
COAL TOWNSHIP, Pa. -- Construction is underway on a new ophthalmology clinic at the Geisinger Specialty Care - Shamokin building (at right), which is located on the grounds of the Geisinger-Shamokin Area Community Hospital (G-SACH). Completion of the 4,000-square foot addition is scheduled for early June.
The new clinic will expand facilities for the diagnoses and treatment of eye disorders and diseases including cataracts, glaucoma, dry eye and uveitis, corneal disease, retina disease, macular degeneration and diabetic retinopathy.
The groundbreaking for the $1.2 million project was on Monday, Jan. 28. It represents the first addition to the Geisinger Specialty Care – Shamokin building since 2007.
Jan. 1 was the one-year anniversary of the merger of Shamokin Area Community Hospital into Geisinger Medical Center.
About Geisinger Health System
Geisinger Health System is an integrated health services organization widely recognized for its innovative use of the electronic health record, and the development of innovative care models such as ProvenHealth Navigator® and ProvenCare®. As the nation’s largest rural health services organization, Geisinger serves more than 2.6 million residents throughout 44 counties in central and northeastern Pennsylvania. The physician-led system is comprised of more than 17,000 employees, including a 900-member multi-specialty group practice, six hospital campuses, two research centers and a 290,000-member health plan, all of which leverage an estimated $5.5 billion positive impact on the Pennsylvania economy. The health system and the health plan have repeatedly garnered national accolades for integration, quality and service. In addition to fulfilling its patient care mission, Geisinger has a long-standing commitment to medical education, research and community service. For more information, visit Geisinger. Follow the latest Geisinger news and more at Twitter and Facebook.
# # # #